1. Home
  2. CATX vs FDMT Comparison

CATX vs FDMT Comparison

Compare CATX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CATX
  • FDMT
  • Stock Information
  • Founded
  • CATX 1983
  • FDMT 2013
  • Country
  • CATX United States
  • FDMT United States
  • Employees
  • CATX N/A
  • FDMT N/A
  • Industry
  • CATX Medical/Dental Instruments
  • FDMT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CATX Health Care
  • FDMT Health Care
  • Exchange
  • CATX Nasdaq
  • FDMT Nasdaq
  • Market Cap
  • CATX 239.0M
  • FDMT 192.2M
  • IPO Year
  • CATX N/A
  • FDMT 2020
  • Fundamental
  • Price
  • CATX $3.04
  • FDMT $6.66
  • Analyst Decision
  • CATX Strong Buy
  • FDMT Buy
  • Analyst Count
  • CATX 11
  • FDMT 9
  • Target Price
  • CATX $12.90
  • FDMT $30.63
  • AVG Volume (30 Days)
  • CATX 696.8K
  • FDMT 520.4K
  • Earning Date
  • CATX 11-11-2025
  • FDMT 11-12-2025
  • Dividend Yield
  • CATX N/A
  • FDMT N/A
  • EPS Growth
  • CATX N/A
  • FDMT N/A
  • EPS
  • CATX N/A
  • FDMT N/A
  • Revenue
  • CATX $1,235,000.00
  • FDMT $33,000.00
  • Revenue This Year
  • CATX N/A
  • FDMT $8,572.97
  • Revenue Next Year
  • CATX N/A
  • FDMT N/A
  • P/E Ratio
  • CATX N/A
  • FDMT N/A
  • Revenue Growth
  • CATX N/A
  • FDMT N/A
  • 52 Week Low
  • CATX $1.60
  • FDMT $2.24
  • 52 Week High
  • CATX $14.19
  • FDMT $17.41
  • Technical
  • Relative Strength Index (RSI)
  • CATX 37.52
  • FDMT 53.43
  • Support Level
  • CATX $3.33
  • FDMT $6.60
  • Resistance Level
  • CATX $3.74
  • FDMT $7.21
  • Average True Range (ATR)
  • CATX 0.25
  • FDMT 0.42
  • MACD
  • CATX -0.01
  • FDMT -0.07
  • Stochastic Oscillator
  • CATX 2.41
  • FDMT 48.25

About CATX Perspective Therapeutics Inc.

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: